Latest Breaking News On - Millennium pharmaceuticals - Page 2 : comparemela.com

Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs

– Total revenues of $881 million in the first quarter – Jakafi® net product revenues of $572 million in Q1 24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of.

United kingdomHong kongUnited statesRetifanlimab zynyzPonatinib iclusigRuxolitinib jakaviCapmatinib tabrectaMinjuvi monjuviPemigatinib pemazyreBaricitinib olumiantTafasitamab monjuviDrug administrationMacrogenics incAmerican academy of dermatologyPharmaceuticals incUs food drug administration

Black Diamond Therapeutics (BDTX) Announces Board Changes

Black Diamond Therapeutics (BDTX) Announces Board Changes
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPrakash ramanAlex maywegWendy dixonShannon campbellMark vellecaAbbott labsIndian institute of technologyUniversity of wisconsinHarvard business schoolBusiness developmentWharton schoolUniversity of michigan ross school businessSenior scientist at millennium pharmaceuticalsDiamond therapeutics incIthaca college

ReNAgade Therapeutics Appoints Joe Bolen, Ph D , Chief Science Innovation Officer

ReNAgade Therapeutics Appoints Joe Bolen, Ph D , Chief Science Innovation Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomJoe bolenHoechst marion rousselEmily brabbitSarah suttonAmitd munshiPuretech healthDevelopment of moderna therapeuticsResearch developmentMillennium pharmaceuticalsKansas state university cancer centerUniversity of nebraskaNational institutes of healthBristol myers squibbExecutive partner

OcuSciences Welcomes Michael Patane, PhD, to its Board of Directors

ANN ARBOR, Mich. (BUSINESS WIRE) Feb 20, 2024

United statesMichael pataneKurt rieggerMitobridge incMedicinal chemistry at millennium pharmaceuticalsOcusciences incKiora pharmaceuticalsEyegate pharmaceuticals incChief scientific officerEyegate pharmaceuticalsGlobal discovery chemistryNovartis institutesBiomedical researchMedicinal chemistryMillennium pharmaceuticalsOcumet beacon

Going Small: Kymera s Juliet Williams Touts Degrader Advantage in SLAS 2024 Keynote

Going Small: Kymera s Juliet Williams Touts Degrader Advantage in SLAS 2024 Keynote
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.

United statesJuliet williamsKevin daviesMillennium pharmaceuticalsSociety of lab automationNovartis institutes of biomedical researchHead of research at kymera therapeuticsKymera therapeuticsLab automationNovartis institutesBiomedical researchBig problemsSmall molecule degradersNew haven